Current Osteoporosis Reports

, Volume 9, Issue 3, pp 112–115 | Cite as

Osteoporosis: A Paradox in Ankylosing Spondylitis

  • Shea Carter
  • Rik J. LoriesEmail author


Ankylosing spondylitis is a chronic and severe inflammatory disease of the axial skeleton and the joints. Inflammation is associated with trabecular bone loss leading to osteoporosis but also with corcal new bone formation leading to progressive ankylosis of the spine and sacroiliac joints. This results in an apparent paradox of bone formation and loss taking place at sites closesly located to each other. Osteoporosis can be explained by the impact of inflammation of the bone remodeling cycle. In contrast, new bone formation has been linked to aberrant acvaon of bone morphogenec protein and Wnt signaling. In this commentary, we review recent data on this bone paradox and highlight recent advances including the effect of current drug therapies and the idenfication of new therapeutic targets.


Osteoporosis Ankylosing spondylitis Ankylosis Arthritis Bone growth Bone loss 



Conflicts of interest: S. Carter: none; R.J. Lories: has been a consultant for MSD, Pfizer, Abbott Laboratories, Roche, and Cellgene; has been on the speakers’ bureaus for Pfizer, MSD, and Abbott Laboratories; and has received travel/accommodations expenses for Pfizer, MSD, and Abbott Laboratories.


  1. 1.
    Appel H et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum. 2006;54(9):2845–51.PubMedCrossRefGoogle Scholar
  2. 2.
    Schett G. Structural bone changes in spondyloarthritis: mechanisms, clinical impact and therapeutic considerations. Am J Med Sci. 2011;341(4):269–71.PubMedCrossRefGoogle Scholar
  3. 3.
    El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine. 2004;71(4):291–5.PubMedCrossRefGoogle Scholar
  4. 4.
    El Maghraoui A et al. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26(10):2205–9.PubMedGoogle Scholar
  5. 5.
    Hanson CA, Shagrin JW, Duncan H. Vertebral osteoporosis in ankylosing spondylitis. Clin Orthop Relat Res. 1971;74:59–64.PubMedCrossRefGoogle Scholar
  6. 6.
    Magrey M, Khan MA. Osteoporosis in ankylosing spondylitis. Curr Rheumatol Rep. 2010;12(5):332–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Maillefert JF et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int. 2001;12(7):605–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Karberg K et al. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol. 2005;32(7):1290–8.PubMedGoogle Scholar
  9. 9.
    Rubinstein HM. Osteoporosis in ankylosing spondylitis. Br J Rheumatol. 1991;30(2):160.PubMedCrossRefGoogle Scholar
  10. 10.
    Will R et al. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet. 1989;2(8678–8679):1483–5.PubMedCrossRefGoogle Scholar
  11. 11.
    Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol. 2004;31(11):2236–41.PubMedGoogle Scholar
  12. 12.
    Ghozlani I et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009;44(5):772–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Dasgupta B et al. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 1992;19(1):22–5.PubMedGoogle Scholar
  14. 14.
    Roche NE et al. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36(9):1286–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Gratacos J et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33(10):927–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Melis L et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69(3):618–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Lubberts E et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol. 2003;170(5):2655–62.PubMedGoogle Scholar
  18. 18.
    Jovanovic DV et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J Immunol. 1998;160(7):3513–21.PubMedGoogle Scholar
  19. 19.
    Kim HR, Lee SH, Kim HY. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford). 2006;45(10):1197–200.CrossRefGoogle Scholar
  20. 20.
    Vis M et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(11):1495–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Appel H et al. Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis. J Rheumatol. 2010;37(4):823–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Lories RJ, Derese I, Luyten FP. Inhibition of osteoclasts does not prevent joint ankylosis in a mouse model of spondyloarthritis. Rheumatology (Oxford). 2008;47(5):605–8.CrossRefGoogle Scholar
  23. 23.
    Obermayer-Pietsch BM et al. Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int. 2003;14(12):995–1000.PubMedCrossRefGoogle Scholar
  24. 24.
    De Keyser F et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep. 2002;4(6):525–32.PubMedCrossRefGoogle Scholar
  25. 25.
    Uderhardt S et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis. 2010;69(3):592–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Visvanathan S et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(2):175–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Toussirot E, Wendling D. Anti-inflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr Opin Rheumatol. 2007;19(4):340–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Division of RheumatologyLaboratory for Skeletal Development and Joint DisordersKU LeuvenBelgium
  2. 2.Division of RheumatologyLaboratory for Skeletal Development and Joint Disorders, KU LeuvenLeuvenBelgium

Personalised recommendations